

Scott Powers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6416592/publications.pdf>

Version: 2024-02-01

13
papers

1,108
citations

1040056

9
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

2714
citing authors

#	ARTICLE	IF	CITATIONS
1	KRAS drives immune evasion in a genetic model of pancreatic cancer. <i>Nature Communications</i> , 2021, 12, 1482.	12.8	105
2	Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer. <i>Cancer Research</i> , 2021, 81, 6090-6105.	0.9	12
3	Comparative single-cell RNA sequencing (scRNA-seq) reveals liver metastasis-specific targets in a patient with small intestinal neuroendocrine cancer. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004978.	1.2	12
4	Identification of targetable BRAF ^V N486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a <i>BRAF</i> -mutant pancreatic adenocarcinoma. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004424.	1.2	21
5	Challenges in Ras therapeutics in pancreatic cancer. <i>Seminars in Cancer Biology</i> , 2019, 54, 101-108.	9.6	29
6	Tandem Duplications May Supply the Missing Genetic Alterations in Many Triple-Negative Breast and Gynecological Cancers. <i>Cancer Cell</i> , 2018, 34, 179-180.	16.8	3
7	A systematic evaluation of nucleotide properties for CRISPR sgRNA design. <i>BMC Bioinformatics</i> , 2017, 18, 297.	2.6	29
8	Functionally Assessing Candidate Drivers Advances Precision Cancer Medicine. <i>Cancer Cell</i> , 2016, 30, 187-189.	16.8	1
9	The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation. <i>Molecular Cell</i> , 2016, 63, 1021-1033.	9.7	82
10	Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas. <i>Scientific Reports</i> , 2016, 6, 27891.	3.3	4
11	Oncogenic Myc Induces Expression of Glutamine Synthetase through Promoter Demethylation. <i>Cell Metabolism</i> , 2015, 22, 1068-1077.	16.2	189
12	In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. <i>Nature Medicine</i> , 2014, 20, 1138-1146.	30.7	242
13	Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening. <i>Cancer Cell</i> , 2011, 19, 347-358.	16.8	379